US2015203830A1PendingUtilityA1

Compositions comprising nucleic acids encoding hiv-1 reverse transcriptase ctl epitopes

59
Assignee: GOVERNMENT OF THE US SECRETARY OF THE DEPARTMEN OF HPriority: Mar 31, 2003Filed: Nov 3, 2014Published: Jul 23, 2015
Est. expiryMar 31, 2023(expired)· nominal 20-yr term from priority
Inventors:Jay A. BerzofskyTakahiro Okazaki
C07K 14/005A61K 2039/54A61K 39/385C12N 2740/16222C12N 2740/16234A61P 31/18A61K 2039/57A61K 2039/545A61K 39/21A61K 2039/53A61K 2039/645C12N 9/1276A61K 2039/6018A61K 2039/55522A61K 39/12C12N 7/00A61K 2039/55566A61K 39/00A61K 2039/5158
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides peptides and proteins for use in second generation HIV vaccines and as diagnostic tools in the treatment and control of HIV infection. The antiviral protection shown by compositions of the present invention has not been previously achieved with an HLA epitope-enhanced vaccine. These findings define a critical balance between MHC affinity and receptor crossreactivity required for effective epitope enhancement and also demonstrate construction and efficacy of such a component of a new generation vaccine.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for preventing or treating an HIV-1 infection comprising administering a dose of an immunostimulating peptide having an amino acid sequence X1LYQYMDDV (SEQ ID NO:1), wherein X1 is any hydrophobic amino acid in an amount effective to induce an immune response capable of preventing HIV-1 infection or reducing HIV-1 viral load in a patient. 
     
     
         2 . The method of  claim 1 , wherein the patient is a human. 
     
     
         3 . The method of  claim 2 , wherein the patient is a primate.

Join the waitlist — get patent alerts

Track US2015203830A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.